Physician profile
Mark R Kahn
NPI 1023017464
$12,995.42
in general payments reported to CMS, 2019-2025
34 companies · $2,481 in 2025
The $2,481 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,302 · 2020: $735 · 2021: $1,610 · 2022: $1,874 · 2023: $2,397 · 2024: $2,597 · 2025: $2,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,967 · Education: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,966.79 |
| Education | $508.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,181.53 | 2019-2025 | |
| Janssen Biotech, INC. | $1,821.70 | 2020-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $1,662.53 | 2019-2025 | |
| Lilly USA, LLC | $1,292.80 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $1,189.60 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $730.24 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $658.76 | 2021-2025 | Dupixent |
| Amgen INC. | $433.14 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $364.32 | 2020-2025 | Nemluvio, Aklief |
| Pfizer INC. | $349.76 | 2019-2025 | |
| Leo Pharma INC. | $308.93 | 2020-2023 | Adbry |
| Almirall LLC | $303.38 | 2019-2024 | Klisyri, Seysara |
| Ucb, INC. | $294.42 | 2021-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $263.85 | 2019-2025 | Winlevi, Absorica Ld |
| Incyte Corporation | $143.18 | 2021-2025 | Opzelura |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $132.30 | 2022-2024 | Vtama |
| Getinge USA Sales, LLC | $112.07 | 2019 | |
| Biofrontera INC. | $109.69 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Strata Skin Sciences, INC. | $106.90 | 2023-2025 | Xtrac |
| Helsinn Therapeutics (U.S.), INC. | $99.55 | 2024-2025 | Valchlor |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.98 | 2023-2025 | Spevigo |
| Glenmark Therapeutics INC. | $51.00 | 2019 | |
| Celgene Corporation | $39.12 | 2019 | |
| Arcutis Biotherapeutics, INC. | $35.44 | 2023-2025 | Zoryve |
| Amneal Pharmaceuticals LLC | $33.55 | 2019 | |
| Merz North America, INC. | $29.47 | 2019 | |
| Verrica Pharmaceuticals INC. | $24.16 | 2023 | Ycanth |
| Organon LLC | $18.76 | 2025 | |
| Dermira, INC. | $18.38 | 2021 | |
| Aroa Biosurgery Incorporated | $17.16 | 2022 | |
| Phadia US INC. | $16.27 | 2023 | Immunocap |
| Botanix Sb INC | $13.67 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.